Jump to contents

Researcher Information

last modified:2017/06/09

Professor MATSUMOTO Kunio

Mail Laboratory Website

Faculty, Affiliation

Cancer Research Institute

College and School Educational Field

Division of Medical Sciences, Graduate School of Medical Science
Division of Cancer Medicine, Graduate School of Medical Science

Laboratory

Division of Tumor Dynamics and Regulation TEL:076-264-6745 FAX:076-234-4513

Academic Background

【Academic background(Doctoral/Master's Degree)】
Osaka University Doctor Biochemistry 198603 Completed
【Academic background(Bachelor's Degree)】
Kanazawa University Biology 198103
【Degree】
Ph.D.

Career

Assistant Professor School of Medicine, Osaka University Assistant Professor(1986/12/16-1990/05/31)
Assistant Professor Faculty of Science, Kyushu University Assistant Professor(1990/06/01-1993/03/31)
Assistant Professor School of Medicine, Osaka University Assistant Professor(1993/06/01-1994/03/31)
Assistant Professor School of Medicine, Osaka University Assistant Professor(1994/04/01-1996/03/31)
Associate Professor School of Medicine, Osaka University Associate Professor(1996/04/01-2001/03/31)
Visiting Associate Professor Brawn University Visiting Associate Professor(1998/08/01-1999/05/31)
Associate Professor Osaka Univ. Graduate School of Medicine Associate Professor(2001/04/01-2007/03/31)
Professor Kanazawa Univ. Cancer Research Institute(2007/04/01-)

Year & Month of Birth

1959/02

Academic Society

Award

○科研費審査委員表彰(2016/09/30)
○科研費審査委員表彰(2016/09/30)
○Nature Medicine-AnGes MG BioMedical Award (Main Award)(2006/05/29)
○The 3rd Biobusiness Competition Japan Special Award by an Examining Comittee(2002/12/12)
○The Most Valuable Article Award for 30 Anniversary Memorial of Nikkei Science Journal(2001/10/06)
○Kudo Foundation Award(1999)
○JB Award from the Japanese Biochemical Society(1996/08/27)
○Incitement Award of the Japanese Cancer Association(1997/09/27)
○Academic Incitement Award of Japanese Industrial Hygiene Dermatology Association(1991/05/31)

Specialities

General medical chemistry

Speciality Keywords

Growth Factor, Metastasis, HGF

Research Themes

Tissue regeneration mediated by HGF-Met. Therapeutic application of HGF. Anti-cancer approach with NK4. Drug discovery targeting HGF-Met. Regulation of #-D cancer invasion and epithelial morphogenesis.

Tissue regeneration mediated by HGF-Met. Therapeutic application of HGF. Anti-cancer approach with NK4.

Books

  •  Matsumoto, K. and Nakamura, T Pleiotropic roles of HGF as a pleiotropic factor in mitogenesis, morphogenesis, and organ regeneration CRC Press and Gakkai Shuppan Center 1994
  •  Matsumoto, K. and Nakamura, T HGF-c-Met receptor pathway in tumor invasion-metastasis and potential cancer treatment with NK4 Kluwer Academic Publisher 2001
  •  Matsuo, Y., Nishi, N., Matsumoto, K., Miyazaki, K., Suzuki, F., and Nishikawa, K 3-[(3-Cholamidopropyl)dimethylammonio]-1-propane sulfonate as anon-cytotoxic stabilizing agent for growth factors Academic Press, Inc 1991
  •  Matsumoto, K. and Nakamura, T Role of hepatocyte growth factor in liver regeneration Inserm/Eurotext 1992
  •  Hashimoto, K., Matsumoto, K., and Yoshikawa, K The effect of vitamin D3 on human keratinocytes and its metabolism Elsevier Science Publishers 1992

show all

  •  Matsumoto, K. and Nakamura, T Roles of HGF as a pleiotropic factor in organ regeneration Birkhauser Verlag 1993
  •  Nakamura, T., Mizuno, K. and Matsumot Hepatocyte growth factor: mitogen, motogen, morphogen, and its roles in tissue regeneration Elsevier 1993
  •  Matsumoto, K. and Nakamura, T Structure, pleiotropic actions, and organotrophic roles of hepatocyte growth factor Springer-Verlag 1994
  •  Matsumoto, K. and Nakamura, T Hepatotrohpic and renotrophic activities of HGF in vivo: possible application of HGF for hepatic and renal diseases Springer-Verlag 1994
  •  Matsumoto, K. and Nakamura, T HGF as a potent renotrophic factor and its therapeutic potential for acute renal failure Churchill Livingstone 1995
  •  Amaike, H., Matsumoto, K., and Nakamura, T Hepatocyte growth factor: pleiotrophic roles for liver regeneration and possible clinical applications Elsevier Science 1995
  •  Matsumoto, K. and Nakamura, T Collagenase and Hyaluronidase John & Wiley 12B 1995
  •  Koshimizu, U., Matsumoto, K., and Nakamura, T Hepatotrophic activities of HGF in liver regeneration after injury and the clinical potentiality for liver diseases Narosa-Springer Verlag 1997
  •  Matsumoto, K. and Nakamura, T HGF: its organotrophic role and therapeutic potential John Willey & Sons 1997
  •  Matsumoto, K. and Nakamura, T Hepatocyte growth factor for tissue organization and its therapeutic application Elseviier Science 1998
  •  Matsumoto, K. and Nakamura, T Hepatocyte growth factor and Met in tumour invasion-metastasis: from mechanisms to cancer prevention Kluwer Academic Publishers 2000
  •  Matsumoto, K. and Nakamura, T Hepatocyte growth factor Academic Press, San Diego 2004
  •  Matsumoto, K. and Nakamura, T.  NK4 gene therapy targeting HGF-Met and angiogenesis. Medical View 22-33 2007/06
  •  Significance, mechanisms, and progress of anticancer drugs targeting HGF-Met.  InTech Open Access Publisher 2011/06
  •  Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Matsumoto K, Yonekura K, Yano S Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation 9 775-783 2014

Papers

  •  Cell-autonomous changes in Met receptor expression regulate the growth and metastatic characteristics in malignant melanoma.  Adachi E, Sakai K, Nishiuchi T, Imamura R, Sato H, Matsumoto K.  Oncotarget 7 70779-70793 2016
  •  Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases.  Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K, Matsumoto K, Hosokawa S, Bessho A, Sendo T, Tanimoto M, Kiura K. Cancer Res 76 1506-1516 2016
  •  Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies. Umitsu M, Sakai K, Ogasawara S, Kaneko M, Asaki R, Tamura-Kawakami K, Kato Y, Matsumoto K, Takagi J. Scientific Reports 6 33149 2016
  •  HGF-MET in cancer progression and biomarker discovery.  Matsumoto K, Umitsu M, De Silva DM, Roy A, Bottaro DP. Cancer Science 108 296-307 2016
  •  Artificial human Met agonists based on macrocycle scaffolds. Ito K†, Sakai K†, Suzuki Y, Ozawa N, Hatta T, Natsume T, Matsumoto K§, Suga H§. Nat Commun 6 6373 2015

show all

  •  A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene. Tada Y, Hiroshima K, Shimada H, Morishita N, Shirakawa T, Matsumoto K, Shingyoji M, Sekine I, Tatsumi K, Tagawa M. SpringerPlus 4 358 2015
  •  Hepatocyte growth factor and Met in drug discovery Sakai K, Aoki S, Matsumoto K J Biochem 157 271-284 2015
  •  Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Matsumoto K, Yonekura K, Yano S J Thorac Oncol, 9 775-783 2014
  •  Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells Tanimoto A, Yamada T, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S Oncotarget 5 4920-4928 2014
  •  Inhibitor of transforming growth factor-β potentiates fibroblast-dependent tumor cell invasion into collagen matrix by increasing secretion of hepatocyte growth factor from fibroblasts Oyanagi J, Kojima N, Higashi S, Kikuchi K, Sakai K, Matsumoto K, Miyazaki K  Exp Cell Res 326 267-279 2014
  •  Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury Adachi E, Hirose-Sugiura T, Kato Y, Ikebuchi F, Yamashita A, Abe T, Fukuta K, Adachi K, Matsumoto K  Pharmacology 94 190-197 2014
  •  Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans Sugiura T, Takahashi S, Sano K, Abe T, Fukuta K, Adachi K, Nakamura T, Matsumoto K, NakamichiN, Kato Y J Pharm Sci 102 237–249 2013
  •  HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells Matsumura A, Kubota T, Taiyoh H, Fujiwara H, Okamoto K, Ichikawa D, Shiozaki A, Komatsu S, Nakanishi M, Kuriu Y, Murayama Y, Ikoma H, Ochiai T, Kokuba Y, Nakamura T, Matsumoto K, Otsuji E Int J Oncol 42 535-542 2013
  •  Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model Hirata Y, Kurobe H, Uematsu E, Yagi S, Soeki T, Yamada H, Fukuda D, Shimabukuro M, Nakayama M, Matsumoto K, Sakai Y, Kitagawa T, Sata M Eur J Pharmacol 699 81-87 2013
  •  The novel PI3K-mTOR inhibitor, BEZ235, circumvents erlotinib- resistance of EGFR mutant lung cancer cells triggered by HGF Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S Int J Cancer 133 505-513 2013
  •  Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes Nakayama M, Sakai K, Yamashita A, Nakamura T, Suzuki Y, Matsumoto K Cytokine 62 446-452 2013
  •  mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S PLoS One 8 e62104 2013
  •  α-Lipoic acid-induced inhibition of proliferation and Met phosphorylation in human non-small cell lung cancer cells Michikoshi H, Nakamura T, Sakai K, Suzuki Y, Adachi E, Matsugo S, Matsumoto K Cancer Lett 335 472-478 2013
  •  Interruption of the HGF paracrine loop by NK4, an HGF antagonist, reduces VEGF expression of CT26 cells Kubota T, Matsumura A, Taiyoh H, Izumiya Y, Fujiwara H, Okamoto K, Ichikawa D, Shiozaki A, Komatsu S, Nakanishi M, Kuriu Y, Murayama Y, Ikoma H, Ochiai T, Nakamura T, Matsumoto K, Nakamura T, Otsuji E Oncol Rep 30 567-572 2013
  •  Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension Nakamura A, Nagaya N, Obata H, Sakai K, Sakai Y, Yoshikawa M, Hamada K, Matsumoto K, Kimura H Circulation J 77 2127-2133 2013
  •  Molecular targeting of hepatocyte growth factor by an antagonist, NK4, in the treatment of rheumatoid arthritis Tsunemi S, Iwasaki T, Kitano S, Matsumoto K, Takagi-Kimura M, Kubo S, Tamaoki T, Sano H Arthritis Res Ther 15 R75 2013
  •  Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in EGFR mutated lung cancer model Hayakawa H, Ichihara E, Ninomiya T, Takata S, Ohashi K, Masayuki Yasugi, Sakai K, Matsumoto K, Takigawa N, Tanimoto M, Kiura K Cancer Science 104 1440-1446 2013
  •  Suppression of fibrogenic gene expression and liver fibrosis using a synthetic prostacyclin agonist Xu Q, Sakai K, Nakayama M, Suzuki Y, Tambo C, Sakai Y, Matsumoto K  Biomed Res 34 241-250 2013
  •  A novel long-acting prostacyclin agonist (ONO-1301) with an angiogenic effect: promoting synthesis of hepatocyte growth factor and increasing cyclic AMP concentration via IP receptor signaling Uchida T, Hazekawa M, Yoshida M, Matsumoto K, Sakai Y J Pharmacol Sci 123 392-401 2013
  •  Yano S. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer Zhao L, Yasumoto K, Kawashima A, Nakagawa T, Takeuchi S, Yamada T, Matsumoto K, Yonekura K, Yoshie O Cancer Sci 104 1640-1646 2013
  •  Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, Ishikawa D, Zhao L, Ebi H, Yasumoto K, Matsumoto K, Yano S PLoS One 8 e84700 2013
  •  Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S J Thoracic Oncol, 7 272-280 2012
  •  Suppression of acute hepatic injury by a synthetic prostacyclin agonist through hepatocyte growth factor expression Xu Q, Nakayama M, Suzuki Y, Sakai K, Nakamura T, Sakai Y, Matsumoto K Am J Physiol 302 G420-G429 2012
  •  A synthetic prostacyclin agonist with thromboxane synthase inhibitory activity, ONO-1301, protects myocardium from ischemia/reperfusion injury Hirata Y, Shimabukuro M, Uematsu E, Soeki T, Yamada H, Sakai Y, Nakayama M, Matsumoto K, Igarashi T, Sata M Eur J Pharmacol 674 352-358 2012
  •  Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Uenaka T, Yano S Clin Cancer Res 18 1663-1671 2012
  •  A sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model Nasu T, Kinomura M, Tanabe K, Yamasaki H, Htay SL, Saito D, Hinamoto N, Watatani H, Ujike H, Suzuki Y, Sugaya T, Sugiyama H, Sakai Y, Matsumoto K, Maeshima Y, Makino H Am J Physiol-Renal Physiol 302 F1616-F1629 2012
  •  Arterial shear stress augments the differentiation of endothelial progenitor cells adhered to VEGF-bound surfaces Suzuki Y, Yamamoto K, Ando J, Matsumoto K, Matsuda T Biochem Biophys Res Commun 423 91-97 2012
  •  Hsp90 inhibition overcomes HGF-triggrering resistance to EGFR-TKIs in EGFR mutant lung cancer by decreasing client protein expression and angiogenesis Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S J Thoracic Oncol, 7 1078-1085 2012
  •  Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S Clin Cancer Res 18 3592-3602 2012
  •  Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Mukaida N, Shimizu E, Nishioka Y, Sone S, Uenaka T, Yano S Am J Pathol 181 1034-1043 2012
  •  Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor to overcome erlotinib resistance in EGFR mutant lung cancer Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, ita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S Mol Cancer Ther 11 2149-2157 2012
  •  Narita I. A novel prostacyclin agonist protects to airway hyperresponsiveness and remodeling in mice Yamabayashi C, Koya T, Kagamu H, Kawakami H, Kimura Y, urukawa T, Sakagami T, Hasegawa T, Sakai Y, Matsumoto K, Nakayama M, Gelfand EW, Suzuki E Am J Respir Cell Mol Biol 47 170-177 2012
  •  Repair of segmental bone defects in rabbit tibia using a complex of b-tricalcium phosphate and hepatocyte growth factor Goshima K, Nakase J, Xu Q, Matsumoto K, Tsuchiya H J Orthopaedic Sci 17 639-648 2012
  •  Cellular injury of cardiomyocytes during hepatocyte growth factor gene transfection with ultrasound-triggered bubble liposome destruction Komamura K, Tatsumi R, Tsujita-Kuroda Y, Onoe T, Matsumoto K, Nakamura T, Miyazaki J, Horio T, Sugimachi M J Drug Delivery 2011 1-8 2011
  •  Induction of donor-specific tolerance using superagonistic CD28 antibody in rat renal allografts: Regulatory T-cell expansion before engraftment may be important Azuma H, Isaka Y, Nomi H, Inamoto T, Li XK, Hőunig T, Takabatake Y, Ichimaru N, Ibuki N, Matsumoto K, Ubai T, Katsuoka Y, Takahara S Transplantation 90 1328-1335 2011
  •  Recombinant human HGF, but not rat HGF, elicits glomerular injury and albuminuria in normal rats via an immune complex-dependent mechanism Mizuno S, Ikebuchi F, Fukuta K, Kato T, Matsumoto K, Adachi K, Nakamura T Clin Exp Pharmacol Physiol 38 192-201 2011
  •  Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S Clin Cancer Res 17 2260-2269 2011
  •  Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells Yasui T, Ohuchida K, Zhao M, Cui L, Onimaru M, Egami T, Fujita H, Ohtsuka T, Mizumoto K, Matsumoto K, Tanaka M Anticancer Res 31(4) 1279-1287 2011
  •  NK4 gene expression enhances 5-fluorouracil-induced apoptosis of murine colon cancer cells Taiyoh H, Kubota T, Fujiwara H, Matsumura A, Murayama Y, Okamoto K, Ichikawa D, Ochiai T, Nakamura T, Matsumoto K, Nakamura T, Otsuji E Anticancer Res 31 2217-2224 2011
  •  3 D collagen and MT1 MMP dependent MMP 2 activation in human malignant mesothelioma cells Sakai K, Nakamura T, Suzuki Y, Imizu T, Matsumoto K  Biochem Biophys Res Commun 412 98-103 2011
  •  Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yasumoto K, Yano S Am J Pathol 179 1483-1493 2011
  •  Promotion of rabbit ligament healing by local delivery of hepatocyte growth factor Ueshima K, Kitaoka K, Nakase J, Xu Q, Matsumoto K, Tsuchiya H J Orthopaedic Sci 16 451-457 2011
  •  A synthetic prostacyclin agonist, ONO-1301, ameliorates ventricular remodeling after acute myocardial infarction via upregulation of HGF in rat Hirata Y, Soeki T, Yamada H, Shiota A, Shimabukuro M, Sakai Y, Nakayama M, Matsumoto K, Igarashi T, Sata M  Biomed Aging Pathol 1 90-96 2011
  •  Hepatocyte growth factor twenty years on: much more than a growth factor Nakamura T, Sakai K, Nakamura T, Matsumoto K J Gastroenterol Hepatol 26 188-202 2011
  •  HGF-antagonists: structure, activities, and anti-cancer approach Sakai K, Nakamura T, Kinoshita T, Nakamura T, Matsumoto K Current Signal Transduction Therapy 6 (2) 191-199 2011
  •  Facilitated tendon-bone healing by local delivery of recombinant hepatocyte growth factor in rabbits Nakase J, Kitaoka K, Matsumoto K, Tomita K Arthroscopy 26 84-90 2010
  •  Hepatocyte growth factor reduces susceptibility to an irreversible epigdermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S Clin Cancer Res 16 174-183 2010
  •  p27 Nuclear localization and growth arrest caused by perlecan knockdown in human endothelial cells Sakai K, Oka K, Matsumoto K, Nakamura T Biochem Biophys Res Commun 392 403-408
  •  hTERT-promotrt-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells Onimaru M, Ohuchida K, Mizumoto K, Nagai E, Cui L, Toma H, Takayama K, Matsumoto K, Hashizume M, Tanaka M  Cancer Sci 101 735-742 2010
  •  Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma Suzuki Y, Sakai K, Ueki J, Xu Q, Nakamura T, Shimada H, Nakamura T, Matsumoto K Int J Cancer 127 1948-1957 2010
  •  Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells Onimaru M, Ohuchida K, Egami T, Mizumoto K, Nagai E, Cui L, Toma H, Matsumoto K, Hashizume M, Tanaka M Cancer Gene Ther 10 36-46 2010
  •  Anti-cancer approach with NK4: Bivalent action and mechanisms Nakamura, T, Sakai, K, Nakamura, T, Matsumoto, K Anti-Cancer Agent Med Chem 10 36-46 2010
  •  Different reactivities of enzyme-linked immunosorbent assays for hepatocyte growth factor Fukuta K, Adachi E, Matsumoto K, Nakamura T Clinica Chimica Acta 402 42-46 2009
  •  Characterization of the enhancing effect of protamine on the proliferative activity of hepatocyte growth factor in rat hepatocytes Liu KX, Kato Y, Matsumoto K, Nakamura T, Kaku T, Sugiyama Y Pharm Res 26 1012-1021 2009
  •  Hepatocyte growth factor prevents multiple organ injuries in endotoxemic mice through a heme oxygenase-1-dependent mechanism Kamimoto M, Mizuno S, Matsumoto K, Nakamura T Biochem Biophys Res Commun 380 333-337 2009
  •  Chemotherapeutic agents potentiate adenoviral gene therapy for pancreatic cancer Egami T, Ohuchida K, Miyoshi K, Mizumoto K, Onimaru M, Toma H, Sato N, Matsumoto K, Tanaka M Cancer Sci 100 722-729 2009
  •  Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models Kishi Y, Kuba K, Nakamura T, Wen J, Suzuki Y, Mizuno S, Nukiwa T, Matsumoto K, Nakamura T Cancer Sci 100 1351-1358 2009
  •  NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells Kubota T, Fujiwara H, Matsumura A, Taiyoh H, Ichikawa I, Okamoto K, Matsumoto M, Nakamura T, Otsuji E Clin Exp Metastasis 26 447-456 2009
  •  Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, Matsumoto K, Nakamura,T Mol. Brain 2  8
  •  Angioinhibitory Action of NK4 Involves Impaired Extracellular Assembly of Fibronectin Mediated by Perlecan-NK4 Association Sakai K, Nakamura T, Matsumoto K, Nakamura T J. Biol. Chem 284 22491-22499 2009
  •  Disease-dependent reciprocal phosphorylation of serine and tyrosine residues of c-Met/HGF receptor contributes disease retardation of a transgenic mouse model of ALS Kadoyama K, Funakoshi H, Ohya-Shimada W, Nakamura T, Matsumoto K, Matsuyama S, Nakamura T Neurosci. Res 65 194-200 2009
  •  Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T-lymphocyte activation Kubota T, Taiyoh H, Matsumura A, Murayama Y, Ichikawa D, Okamoto O, Fujiwara H, Ikoma H, Nakanishi N, Kikuchi S, Ochiai T, Sakakura C, Kokuba Y, Suzuki Y, Matsumoto K, Nakamura T, Otsuji E Int J Cancer 125 2879-2886 2009
  •  Up-regulation of integrin-b3 in radioresistant pancreatic cancer impairs adenovirus-mediated gene therapy Egami T, Ohuchida K, Yasui T, Mizumoto K, Onimaru M, Toma H, Sato N, Matsumoto K, Tanaka M Cancer Sci 100 1902-1907 2009
  •  Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin Tamase A, Muraguchi T, Naka K, Tanaka S, Kinoshita M, Hoshii T, Ohmura M, Ooshio T, Nakada M, Sawamoto K, Matsumoto K, Oshima M, Asano M, Saya H, Okano H, Suda T, Hamada J, Hirao A Proc Natl Acad Sci USA 106 17163-17168 2009
  •  Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors Wang W, Li Q, Matsumoto K, Kayano Y, Matsumoto I, Oda M, Watanabe G, Nishioka Y, Sone S, Yano S Clin. Cancer Res 15(21) 6630-6638 2009
  •  Gelfand E, Kanehiro A. Growth factors temporally associate with airway responsiveness and inflammation in allergen-exposed mice Ito W, Tanimoto M, Ono K, Mizuno S, Yoshida A, Koga H, Fuchimoto Y, Kondo N, Tanimoto Y, Kiura K, Matsumoto K, Kataoka M, Nakamura T Int Arch Allergy Immunol 145 324-339 2008
  •  Reduction of fibrosis in a rat model of non-alcoholic steatohepatitis cirrhosis by human HGF gene transfection using electroporation Kiyama S, Yamada T, Iwata H, Sekino T, Matsuo H, Yoshida N, Miyahara T, Umeda Y, Matsuno Y, Kimura M, Matsumoto K, Nakamura T, Takemura H J Gastroenterol Hepatol 23 e471-476 2008
  •  Generation of engineered recombinant hepatocyte growth factor cleaved and activated by Genenase I Hayata D, Fukuta K, Matsumoto K, Adachi E, Hanada K, Adachi K, Nakamura T I. J Biotechnol 133 478-485 2008
  •  Hepatocyte growth factor improves synaptic localization of the NMDA receptor and intracellular signaling after excitotoxic injury in cultured hippocampal neurons Akita H, Takagi N, Ishihara N, Takagi K, Murotomi K, Funakoshi H, Matsumoto K, Nakamura T, Takeo S Exp Neurol 210 83-94 2008
  •  Regulation of cell migration and cytokine production by HGF-like protein (HLP)/macrophage stimulating protein (MSP) in primary microglia Suzuki Y, Funakoshi H, Machide M, Matsumoto K, Nakamura T Biomed Res 29 77-84 2008
  •  Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake Egami T, Ohuchida K, Mizumoto K, Onimaru M, Toma H, Nishio S, Nagai E, Matsumoto K, Nakamura T, Tanaka M Clin. Cancer Res 14 1859-1867 2008
  •  Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with EGF Receptor activating mutations Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S  Cancer Res 68 9479-9487 2008
  •  NK4 gene therapy targeting HGF-Met and angiogenesis Matsumoto K, Nakamura T Front Biosci 13 1943-1951 2008
  •  The functions and possible significance of Kremen as the gatekeeper of Wnt signaling in development and pathology Nakamura T, Nakamura T, Matsumoto K J Cell Mol Med 12 391-408 2008
  •  Hepatocyte growth factor gene therapy for hypertension Komamura K, Miyazaki J, Imai E, Matsumoto K, Nakamura T, Hori M Methods Mol Biol 423 393-404 2008
  •  Hepatocyte growth factor as a renotrophic and anti-fibrotic regulator in chronic renal disease Mizuno S, Matsumoto K, Nakamura T Front Biosci 13 7072-7086 2008
  •  Hepatocyte Growth Factor and Met in Tumor Biology and Therapeutic Approach with NK4 Matsumoto K, Nakamura T, Sakai K, Nakamura T 8 3360-3370 2008
  •  A genomic analysis of adult T-cell leukemia Choi YL, Tsukasaki K, O'neill MC, Yamada Y, Onimaru Y, Matsumoto K, Ohashi J, Yamashita Y, Tsutsumi S, Kaneda R, Takada S, Aburatani H, Kamihira S, Nakamura T, Tomonaga M, Mano H Oncogene 26 1245-1255 2007
  •  NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells in vivo; molecular targeting of angiogenic growth factor Du W, Hattori Y, Yamada T, Matsumoto K, Nakamura T, Sagawa M, Otsuki T, Niikura T, Nukiwa T, Ikeda Y Blood 109 3042-3049 2007
  •  Stimulation of Hepatocyte Growth Factor Production by Heparin-derived Oligosaccharides Sakiyama R, Fukuta K, Matsumoto K, Furukawa M, Takahashi Y, Nakamura T J Biochem 141 653-660 2007
  •  Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T Biochem Biophys Res Commun 358 117-123 2007
  •  Hepatocyte growth factor promotes the number of PSD-95 clusters in young hippocampal neurons Nakano M, Takagi N, Takagi K, Funakoshi H, Matsumoto K, Nakamura T, Takeo S Exp Neurol 207 195-202 2007
  •  Hepatocyte growth factor prevents pulmonary ischemia-reperfusion injury in mice Makiuchi A, Yamaura K, Mizuno S, Matsumoto K, Nakamura T, Amano J, Ito K J. Heart Lung Transplant 26 935-943 2007
  •  Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells Kanehira M, Xin H, Hoshino K, Maemondo M, Mizuguchi H, Hayakawa T, Matsumoto K, Nakamura T, Nukiwa T, Saijo Y Cancer Gene Ther 14 894-903 2007
  •  Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressatrade mark) for disseminated peritoneal scirrhous gastric cancer Namiki Y, Namiki T, Yoshida H, Date M, Yashiro M, Matsumoto K, Nakamura T, Yanagihara K, Tada N, Satoi J, Fujise K Int J Cancer 118 1545-1555 2006
  •  Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/HGF receptor and LAR protein tyrosine phosphatase Machide M, Hashigasako A, Matsumoto K, Nakamura T J Biol Chem 281 8765-8772 2006
  •  Enhanced suppression of tumor growth using a combination of NK4 plasmid DNA-PEG engrafted cationized dextran complex and ultrasound irradiation Hosseinkhani H, Kushibiki T, Matsumoto K, Nakamura T, Tabata Y Cancer Gene Therapy 13 479-489 2006
  •  Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival Ogura Y, Mizumoto K, Nagai E, Murakami M, Inadome N, Saimura M, Matsumoto K, Nakamura T, Maemondo M, Nukiwa T, Tanaka M Cancer Gene Therapy 13 520-529 2006
  •  Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line Ono K, Kamiya S, Akatsu T, Nakamura C, Li M, Amizuka N, Matsumoto K, Nakamura T, Kugai N, Wada S BALB/c-MC. Bone 39 27-34 2006
  •  Different activity regulation and subcellular localization of LIMK1 and LIMK2 during cell cycle transition Sumi T, Hashigasako A, Matsumoto K, Nakamura T Exp Cell Res 312 1021-2030 2006
  •  Intraventricular administration of hepatocyte growth factor treats mouse communicating hydrocephalus induced by transforming growth factor-b1 Tada T, Zhan H, Tanaka Y, Hongo K, Matsumoto K, Nakamura T Neurobiol Disease 21 576-586 2006
  •  Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy Azuma J, Taniyama Y, Takeya Y, Iekushi K, Aoki M, Dosaka N, Matsumoto K, Nakamura T, Ogihara T, Morishita R Gene Therapy 13 1206-1213 2006
  •  Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice Son G, Hirano T, Seki E, Iimuro Y, Nukiwa T, Matsumoto K, Nakamura T, Fujimoto J J Hepatol 45 688-695 2006
  •  Prevention of apoptosis-inducing factor translocation is a possible mechanism for protective effects of hepatocyte growth factor against neuronal cell death in the hippocampus after transient forebrain ischemia Niimura M, Takagi N, Takagi K, Mizutani R, Ishihara N, Matsumoto K, Funakoshi H, Nakamura T, Takeo S J Cereb Blood Flow Metab 26 1354-1365 2006
  •  Liver targeting of plasmid DNA with a cationized pullulan for tumor suppression Jo J, Yamamoto M, Matsumoto K, Nakamura T, Tabata Y J Nanosci Nanotechnol 6 2853-2859 2006
  •  The protective effect of hepatocyte growth factor against cell death in the hippocampus after transient forebrain ischemia is related to the improvement of apurinic/apyrimidinic endonuclease/redox factor-1 level and inhibition of NADPH oxidase activity Niimura M, Takagi N, Takagi K, Mizutani R, Tanonaka K, Funakoshi H, Matsumoto K, Nakamura T, Takeo S Neurosci Lett 407 136-140 2006
  •  Model of vasculogenesis from embryonic stem cells for vascular research and regenerative medicine Nakagami H, Nakagawa N, Takeya Y, Kashiwagi K, Ishida C, Hayashi S, Aoki M, Matsumoto K, Nakamura T, Ogihara T, and Morishita R Hypertension 48 112-119 2006
  •  Hepatocyte growth factor attenuates cerebral ischemia-induced increase in permeability of the blood-brain barrier and decreases in expression of tight junctional proteins in cerebral vessels Date I, Takagi N, Takagi K, Tanonaka K, Funakoshi H, Matsumoto K, Nakamura T, Takeo S Neurosci Lett 407 141-145 2006

Conference Presentations

Arts and Fieldwork

Patent

Theme to the desired joint research

Grant-in-Aid for Scientific Research

○「肝傷害にともなうHGF(肝細胞増殖因子)の発現誘導と発現誘導因子の実体解明」(1991-) 
○「肝傷害にともなうHGF(肝細胞増殖因子)の発現誘導と発現誘導因子の実体解明」(1992-) 
○「インジュリン(HGF発現誘導因子)の精製と構造解析」(1993-) 
○「HGFからみた癌細胞と間質細胞の相互作用に関する分子細胞生物学的研究」(1994-) 
○「「脳細胞の選択的死と機能分子」」(1994-) 
○「増殖因子からみた癌細胞と間質細胞の相互作用―その分子機構―」」(1994-) 
○「「脳細胞の選択的死と機能分子」」(1995-) 
○「初期発生ならびに器官形成過程におけるHGFならびにそのファミリー分子の機能」(1995-) 
○「「増殖因子からみた癌細胞と間質細胞の相互作用―その分子機構―」」(1995-) 
○「「脳細胞の選択的死と機能分子」」(1996-) 
○「初期発生ならびに器官形成過程におけるHGFならびにそのファミリー分子の機能」(1996-) 
○「「ヒト消化器がんの増殖制御機構」」(1996-) 
○「LIMキナーゼの分子細胞生物学的研究ならびに遺伝子欠損マウス作製による機能解析」(1997-) 
○「「ヒト消化器がんの増殖制御機構」」(1997-) 
○「遺伝子治療基盤に関する研究」(1997-1997) 
○「LIMキナーゼの分子細胞生物学的研究ならびに遺伝子欠損マウス作製による機能解析」(1998-) 
○「「ヒト消化器がんの増殖制御機構」」(1998-) 
○「「糖鎖リモデリング」」(1998-) 
○「HGFクリングルによる血管抑制と新規クリングル分子の同定・血管調節に関する研究」(1999-) 
○「難治性疾患に対するHGF(肝細胞増殖因子)の抗線維化機構の解析と治療への応用」(1999-) 
○「HGFクリングルによる血管抑制と新規クリングル分子の同定・血管調節に関する研究」(2000-) 
○「難治性疾患に対するHGF(肝細胞増殖因子)の抗線維化機構の解析と治療への応用」(2000-)
○「NK4(HGFアンタゴニスト・抗血管新生因子)による悪性腫瘍の治療研究」(2000-) 
○「傷害察知と連携したMet/HGF受容体シグナル変換能の調節を介した再生制御の研究」(2001-) 
○「難治性疾患に対するHGF(肝細胞増殖因子)の抗線維化機構の解析と治療への応用」(2001-) 
○「NK4(HGFアンタゴニスト・抗血管新生因子)による悪性腫瘍の治療研究」(2001-) 
○「c-Met/HGFレセプターを介した傷害認識-再生駆動システムの解析」(2001-) 
○「傷害察知と連携したMet/HGF受容体シグナル変換能の調節を介した再生制御の研究」(2002-) 
○「NK4(HGFアンタゴニスト/血管新生抑制因子)による悪性腫瘍の治療研究」(2002-) 
○「傷害察知と連携したMet/HGF受容体シグナル変換能の調節を介した再生制御の研究」(2003-) 
○「中枢神経系の損傷修復促進のための開発的研究」(1997-1999) 
○「Malignostatin(HGF/NK4)による癌浸潤・転移および腫瘍血管新生の抑制」(1999-1999) 
○「中枢神経系の修復機能の解明と治療応用に関する開発的研究」(2000-2002) 
○「新しいがん薬物療法の研究」(2000-2003) 
○「発がん過程におけるがんと間質の相互作用に関する研究」(2003-2003) 
○「がん生物像を規定するがん組織内微小環境に関する研究」(2004-2005) 
○「Met/HGF受容体シグナル変換能の制御を介した組織再生・恒常性維持機構の研究」(2006-2007) 
○「Met/HGF受容体シグナル伝達能のON-OFF制御を介した組織再生制御の研究」(2008-2010) 
○「3-D浸潤性獲得と上皮形態形成制御を基盤とする腫瘍悪性化機構の研究」(2012-2014) 

Classes (Bachelors)

Classes (Graduate Schools)

○Tumor Biochemistry(2017)
○Cancer molecular pathology 2(2017)
○Cancer molecular pathology 2(2017)
○Cancer molecular pathology 2(2017)
○Molecular Oncology(2017)
○Tumor Biology(2017)
○Tumor Biology(2017)
○Cancer molecular pathology 2(2017)
○Biology of Cancer 2B(2017)
○Biology of Cancer 2A(2017)
○Medical Sciences(2016)
○Tumor Biochemistry(2016)
○Tumor Biology(2016)
○Tumor Biology(2016)
○Biology of Cancer 2B(2016)
○Biology of Cancer 2A(2016)
○Cancer molecular pathology 2(2016)
○Molecular Oncology(2016)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top